Latest Oncology News

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

September 19th 2021

Antonia DePace

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

Balstilimab plus Zalifrelimab Displays Strong Efficacy, Survival Benefits in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Kyle Doherty

The anti-PD-1 antibody balstilimab in combination with the anti-CTLA-4 antibody zalifrelimab exhibited impressive response rates, duration of response, and overall survival in patients with previously treated recurrent/metastatic cervical cancer.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19th 2021

Gina Mauro

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

Tisotumab Vedotin Plus Frontline Carboplatin and Second-/Third-Line Pembrolizumab Demonstrates Notable Activity in Recurrent/Metastatic Cervical Cancer

September 19th 2021

Caroline Seymour

Tisotumab vedotin elicited significant responses without prohibitive toxicity in combination with carboplatin as frontline therapy, as well as in combination with pembrolizumab as second- or third-line therapy in patients with recurrent or metastatic cervical cancer.

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

Adagrasib Shows Impressive Activity in KRAS G12C–Mutant CRC

September 19th 2021

Conor Killmurray

Adagrasib alone or in combination with cetuximab elicited encouraging antitumor activity and safety in heavily pretreated patients with KRAS G12C–mutant colorectal cancer, according to findings from the phase 1/2 KRYSTAL-1 trial.

Latest Oncology Videos

All Oncology News

Pirtobrutinib Offers a Potential Strategy to Overcome BTK Inhibitor Resistance in CLL

September 17th 2021

Jessica Hergert

Catherine Callaghan Coombs, MD, discusses the rationale for the BRUIN study, key efficacy and safety findings, and next steps with pirtobrutinib in chronic lymphocytic leukemia.

Frontline Immunotherapy Improves Survival in Advanced RCC, But Benefit to Be Determined for Favorable-Risk Subset

September 16th 2021

Hayley Virgil

Frontline immunotherapy resulted in improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma; however, determining the benefit in those with favorable-risk disease must be examined further.

Brigatinib Maintains Superior PFS Benefit Over Crizotinib With High Intracranial Efficacy in ALK+ NSCLC

September 16th 2021

Kristi Rosa

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

Global Maximum-Tolerated Dose of Mobocertinib Found Tolerable in Japanese Patients With NSCLC

September 16th 2021

Caroline Seymour

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

Mobocertinib Shows Improved Responses Vs Real-World Data in Advanced EGFR Exon 20 Insertion+ NSCLC

September 16th 2021

Wayne Kuznar

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Neel on Maximizing Research Strides in Oncology

September 16th 2021

OncLive Staff

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

Linagliptin/Atezolizumab Combo Shows Limited Clinical Activity in Second-Line Gastric/GEJ Cancer

September 16th 2021

Wayne Kuznar

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

TMB-H Status Linked With High Responses to Dostarlimab in Endometrial Cancer

September 16th 2021

Courtney Marabella

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

Pembrolizumab/Axitinib Combo Demonstrates Long-Term OS Benefit in Clear Cell RCC

September 16th 2021

Tony Berberabe

Patients with clear cell renal cell carcinoma who received the combination of pembrolizumab and axitinib over sunitinib showed a benefit in adjusted overall survival and type and timing of subsequent therapy in a second interim analysis of the phase 3 KEYNOTE-426 study.

Darolutamide Plus ADT Demonstrates Similar Safety Profile Vs ADT Alone in nmCRPC

September 16th 2021

Lindsay Fischer

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Darolutamide Favorably Affects Episodic Memory Vs Enzalutamide in mCRPC

September 16th 2021

Audrey Sternberg

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

FDA Greenlights Companion Diagnostic for Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

September 16th 2021

Kristi Rosa

The FDA has granted premarket approval to the Oncomine Dx Target Test for use as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations who may be eligible to receive the newly approved small molecule TKI mobocertinib.

Giants of Cancer Care® Announces Ninth Annual Class of Inductees

September 16th 2021

OncLive®, the nation's leading multimedia resource for oncology professionals, and Pfizer, its platinum sponsor, are pleased to announce the finalists of the ninth annual Giants of Cancer Care® program.

ESMO 2021: Oncology Experts Share Game-Changing Data in Breast Cancer, Gynecologic Malignancies

September 16th 2021

Gina Mauro

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Trilaciclib: Treatment Considerations

September 16th 2021

Charu Aggarwal, MD, MPH, University of Pennsylvania Hospital

Advantages associated with the administration of trilaciclib in appropriate patients receiving a chemotherapy-containing regimen for extensive-stage small cell lung cancer.

See All News